RI-MUHC and McGill awarded $5.1 million for infectious disease research
A new grant from the Canada Foundation for Innovation will invest in leading edge Containment Level 3...
Instrument Demo – Zeiss Axio Observer 7
Hosted by the Molecular Imaging Platform in collaboration with Zeiss Canada
RI-MUHC trainee Prisca Bustamante honoured by Mitacs Award for Outstanding Innovation
Doctoral student develops world's first non-invasive blood screening test for uveal melanoma
Multiplexed technologies are paving the way to rapid and equitable screening for sexually transmitted infections
Work by RI-MUHC postdoc Angela Karellis published in The Lancet...
RI-MUHC team detects impact of HIV antiretroviral therapy on the anti-tuberculosis immune response
Alveolar macrophages, cells important for protection from tuberculosis infection, are adversely impacted by...
Platform Expo 2021
The RI-MUHC Technology Platforms invite you to attend the Platform Expo Webinar on October 7, 2021.
New G protein inhibitor identified, with potential for cancer therapies
RI-MUHC team publishes study in Nature Communications describing a novel molecule that inhibits growth of cancer cells
RI-MUHC team identifies potential diagnostic biomarker for pancreatic cancer
Study demonstrates that regenerative protein 3A/3B promotes a newly recognized precursor of pancreatic...
How does the hunger-suppressing hormone leptin cross the blood-brain barrier?
Specialized cells called pericytes play a key role, reveals new work from researchers at the RI-MUHC
RI-MUHC study explores how to overcome the resistance of bladder tumours to radiation therapy
Work published in Nature Communications demonstrates a...